SCHEDULE: Morgan Stanley Discloses 6.8% Stake in Beta Bionics

Morgan Stanley and its subsidiary have reported a beneficial ownership of 6.8% in Beta Bionics, Inc.'s common stock.

Summary

• Morgan Stanley, along with its wholly-owned subsidiary Morgan Stanley Capital Services LLC, has filed a Schedule 13G.
• The filing discloses beneficial ownership of common stock in Beta Bionics, Inc. (CUSIP: 08659B102).
• As of June 30, 2025, Morgan Stanley beneficially owns an aggregate of 2,928,838 shares, representing 6.8% of the class.
• Morgan Stanley Capital Services LLC beneficially owns 2,899,502 shares, representing 6.7% of the class.
• The securities were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of the issuer.

Sentiment

Score: 5

Explanation: Neutral, as this is a factual disclosure of beneficial ownership and does not contain performance or operational details about the issuer.

Future Outlook

The filing does not provide any forward-looking statements or guidance regarding Beta Bionics, Inc.'s future operations or financial performance. It solely reports a beneficial ownership stake.

Industry Context

This filing indicates a significant institutional investment by a major financial services firm, Morgan Stanley, in Beta Bionics, Inc. Such disclosures are common for large investment firms that cross the 5% beneficial ownership threshold in publicly traded companies, reflecting their portfolio holdings rather than specific strategic industry moves by the issuer.

Stakeholder Impact

• Shareholders: The disclosure of a significant institutional holder like Morgan Stanley may be viewed positively by some investors, potentially signaling confidence in Beta Bionics, Inc. However, the filing explicitly states the shares are held in the ordinary course of business and not for control.

Key Dates

Keywords

Beta Bionics, Morgan Stanley, Beneficial Ownership, Schedule 13G, Common Stock, Institutional Ownership, Investment, Financial Services